We and others recently reported recurrent mutations in the CoREST-binding protein ZNF217 in tumor samples from patients with primary mediastinal B cell lymphoma (PMBCL), gray zone lymphoma and Hodgkin lymphoma (HL) with the highest prevalence in PMBCL (~30%) [7, 15–20]. This evidence concerns the gene ZNF217 and neoplasm.